Fresenius Medical Care's parent company sells 10.6 million shares, the proceeds of which will be used to reduce its leverage and achieve higher profits in 2025.

Targeted alpha therapy shows promise in treating neuroendocrine tumours, offering hope where beta therapies fall short.

With cancer claiming over 254 Filipino lives daily and more than 150,000 new cases reported annually, urgent and collective action is needed to strengthen the country’s cancer care system.

The Port Authority of New York and New Jersey and Fraport, manager of John F. Kennedy International Airport’s Terminal 5, ...

Optellum, the leader in AI-enabled lung cancer diagnosis, today announced it has entered a strategic agreement with Volpara Health, a Luni ...

All year-end and CSV data is "as traded on the day" and ignores corporate actions (e.g. share splits) ...